Wave Life Sciences stock drops 6% as WVE traders size up next obesity data
NEW YORK, Jan 3, 2026, 20:55 ET — Market closed Wave Life Sciences Ltd (WVE) shares closed down 6.2% on Friday at $15.95, ending the first full U.S. trading session of 2026 with a sharp pullback. The slide matters because Wave has become an event-driven obesity trade after a December clinical update on its experimental fat-loss drug drew heavy attention from biotech investors. With U.S. markets closed for the weekend, traders are now looking past Friday’s drop to the next scheduled clinical follow-ups and to how Wave’s recent fundraising affects the stock’s risk-reward into 2026. Nasdaq trading data showed WVE